A study found that for the assessment of clinical outcomes based on the detection of common BRAF, KRAS, and EGFR mutations, sEV nucleic acids are more sensitive that plasma ctDNA in patients with NSCLC [34]. Here, BRAF is linked to non-small cell lung carcinoma.